Pharma major Lupin Ltd on Tuesday announced the launch of generic Abacavir and Lamivudine tablets for HIV in the US.
In a regulatory filing in BSE, the company said it has launched Abacavir and Lamivudine tablets 600 mg/300 mg after an approval from the United States Food and Drug Administration (USFDA) earlier.
According to Lupin, Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company's Epzicom tablets, 600 mg/300 mg.
It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Epzicom tablets had US sales of $388.1 million, the company said.
--IANS
vj/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app